Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
cancer published : Today exchanges : Nasdaq save search
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting
Published: 2024-04-24 (Crawled : 20:00) - globenewswire.com
FGEN | $0.9844 -8.0% -8.7% 2.2M
|
Health Technology
| Email alert
Add to watchlist
fg-3246 cancer meeting study
Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
Published: 2024-04-24 (Crawled : 19:00) - biospace.com/
NVCR | $12.35 2.45% 2.39% 1.1M
|
Health Technology
|
| O: -0.25%
H: 0.0%
C: 0.0%
lung asco cancer cell for trial results
First Approval for Rare Pediatric Cancer; New OTC Opioid Overdose Option
Published: 2024-04-24 (Crawled : 16:00) - biospace.com/
ABT | News | $106.89 -0.65% -0.22% 5.1M
|
Health Technology
|
| O: -1.04%
H: 0.0%
C: 0.0%
PRGO | $31.23 2.43% 0.0% 960K
|
Health Technology
|
| O: 0.1%
H: 0.0%
C: 0.0%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -1.02%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.82%
H: 0.0%
C: 0.0%
rare first opioid approval for
Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
Published: 2024-04-24 (Crawled : 14:00) - globenewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.82%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: -0.11%
H: 0.0%
C: 0.0%
asco tumors treatment blood for
Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers
Published: 2024-04-24 (Crawled : 12:00) - globenewswire.com
KTTA | $7.09 -1.19% 910
|
| Email alert
Add to watchlist
pas-004 first trial therapeutics
Bionano Announces Publication Showing OGM’s High Resolution Structural Variation Detection in Cancer Validated by Cas9-Directed Nanopore Sequencing
Published: 2024-04-24 (Crawled : 12:00) - globenewswire.com
BNGO | $0.7655 -3.64% -3.78% 790K
|
Health Technology
|
| O: 0.63%
H: 0.0%
C: 0.0%
cancer publication
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers
Published: 2024-04-24 (Crawled : 11:00) - globenewswire.com
HOOK | $0.843 10.2% 9.25% 10M
|
Health Technology
|
| O: 13.6%
H: 0.0%
C: 0.0%
hb-700 fda pharma drug treatment clearance for application
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.